Scott C. Donnelly
Known title: Chairman, President & CEOCIK: 0001233158
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Textron Q3 2026 Earnings Preview and Industry News. Investors are focusing on Textron's upcoming Q3 2026 earnings report, which is a key upcoming event for the company. Recent news also highlights broader defense sector developments, including a major amphibious vehicle deal for a competitor and new Pentagon drone initiatives. These industry updates provide context for Textron's position in the aerospace and defense market ahead of its financial results.
Transaction History
| MDT | ▼ Sell | Tax Withholding | 207 | $17K | 4/28/2026 | View on chart |
| MDT | ▲ Buy | Grant | 2,111 | $0 | 4/27/2026 | View on chart |
| TXT | ▲ Buy | Grant | 13,017 | $0 | 3/1/2026 | View on chart |
| TXT | ▼ Sell | Tax Withholding | 19,777 | $2.0M | 3/1/2026 | View on chart |
| TXT | ▲ Buy | Option Exercise | 219,619 | $10.9M | 2/13/2026 | View on chart |
| TXT | ▼ Sell | Open Market | 130,168 | $12.8M | 2/13/2026 | View on chart |
| TXT | ▼ Sell | Open Market | 222 | $22K | 2/13/2026 | View on chart |
| TXT | ▼ Sell | Open Market | 89,229 | $8.8M | 2/13/2026 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 216 | $18K | 4/29/2025 | View on chart |
| MDT | ▲ Buy | Grant | 2,083 | $175K | 4/28/2025 | View on chart |
| TXT | ▲ Buy | Grant | 47,232 | $0 | 3/1/2025 | View on chart |
| TXT | ▼ Sell | Tax Withholding | 16,765 | $1.3M | 3/1/2025 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 192 | $16K | 5/1/2024 | View on chart |
| MDT | ▲ Buy | Grant | 2,165 | $175K | 4/29/2024 | View on chart |
| TXT | ▼ Sell | Tax Withholding | 49,303 | $4.4M | 3/1/2024 | View on chart |
| TXT | ▲ Buy | Grant | 32,547 | $0 | 3/1/2024 | View on chart |
| TXT | ▲ Buy | Grant | 43,553 | $0 | 3/1/2024 | View on chart |
| TXT | ▲ Buy | Option Exercise | 238,578 | $8.2M | 2/15/2024 | View on chart |
| TXT | ▼ Sell | Open Market | 238,578 | $20.6M | 2/15/2024 | View on chart |
| TXT | ▲ Buy | Option Exercise | 194,546 | $8.6M | 2/14/2024 | View on chart |
| TXT | ▼ Sell | Open Market | 194,546 | $16.8M | 2/14/2024 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 169 | $15K | 5/2/2023 | View on chart |
| MDT | ▲ Buy | Grant | 1,930 | $175K | 5/1/2023 | View on chart |
| TXT | ▲ Buy | Grant | 44,583 | $0 | 3/1/2023 | View on chart |
| TXT | ▼ Sell | Tax Withholding | 43,984 | $3.2M | 3/1/2023 | View on chart |
| TXT | ▲ Buy | Option Exercise | 222,319 | $8.8M | 2/21/2023 | View on chart |
| TXT | ▼ Sell | Open Market | 198,876 | $14.6M | 2/21/2023 | View on chart |
| TXT | ▼ Sell | Open Market | 23,443 | $1.7M | 2/21/2023 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 262 | $27K | 5/3/2022 | View on chart |
| MDT | ▲ Buy | Grant | 1,697 | $0 | 5/2/2022 | View on chart |
| TXT | ▼ Sell | Tax Withholding | 26,366 | $1.9M | 3/1/2022 | View on chart |
| TXT | ▲ Buy | Grant | 38,997 | $0 | 3/1/2022 | View on chart |
| TXT | ▲ Buy | Option Exercise | 136,854 | $3.9M | 2/22/2022 | View on chart |
| TXT | ▲ Buy | Option Exercise | 91,932 | $2.6M | 2/22/2022 | View on chart |
| TXT | ▲ Buy | Option Exercise | 14,371 | $409K | 2/22/2022 | View on chart |
| TXT | ▼ Sell | Open Market | 91,932 | $6.3M | 2/22/2022 | View on chart |
| TXT | ▼ Sell | Open Market | 14,371 | $1.0M | 2/22/2022 | View on chart |
| TXT | ▼ Sell | Open Market | 136,854 | $9.3M | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MiniMed completes separation from Medtronic
Medtronic has finalized the separation of its MiniMed insulin pump business, which is now operating as an independent company with a new board of directors. This corporate restructuring marks a significant shift in Medtronic's portfolio structure. Meanwhile, the company was named to the TIME Best Inventions of 2026 list for its Stealth AXiS surgical system and Corsano wearable, highlighting continued innovation in its remaining product lines.
MiniMed completes separation from Medtronic. Medtronic has finalized the separation of its MiniMed insulin pump business, which is now operating as an independent company with a new board of directors. This corporate restructuring marks a significant shift in Medtronic's portfolio structure. Meanwhile, the company was named to the TIME Best Inventions of 2026 list for its Stealth AXiS surgical system and Corsano wearable, highlighting continued innovation in its remaining product lines.